MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
512.13%
Quick Ratio
512.13%
Cash Ratio
141.80%
Unit: Thousand (K) dollars
Assets Breakdown
    • Available-for-sale investments
    • Cash and cash equivalents
    • Operating lease, right-of-use as...
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Long-term operating lease liabil...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
16,160
10,008
10,743
6,150
Available-for-sale investments
41,258
56,505
67,944
84,052
Other receivables
426
477
873
1,042
Prepaid expenses
518
586
677
1,770
Total current assets
58,362
67,576
80,237
93,014
Restricted cash
1,495
1,805
2,235
2,712
Property and equipment, gross
-
-
9,091
-
Less accumulated depreciation and amortization
-
-
4,828
-
Property and equipment, net
4,127
4,237
4,263
4,429
Operating lease, right-of-use assets
5,353
5,441
5,524
5,603
Financing lease, right-of-use assets
298
447
596
745
Other assets
190
148
148
149
Total assets
69,825
79,654
93,003
106,652
Accounts payable
3,242
2,755
3,891
4,064
Accrued expenses
6,690
7,458
9,791
10,185
Current portion of operating lease liability
946
890
836
799
Current portion of financing lease liability
518
596
630
630
Total current liabilities
11,396
11,699
15,148
15,678
Long-term operating lease liability, net of current portion
9,799
10,063
10,308
10,532
Long-term financing lease liability, net of current portion
36
151
259
398
Common stock, 0.001 par value per share 340,000,000 authorized shares as of june 30, 2026 (unaudited) and december 31, 2025 issued and outstanding shares - 98,087,425 as of june 30, 2026 (unaudited) and 98,031,104 as of december 31, 2025
98
98
98
98
Additional paid-in capital
676,022
674,861
673,554
672,339
Accumulated other comprehensive loss
-68
-70
-8
-1
Accumulated deficit
-627,264
-616,955
-606,164
-592,201
Total atyr pharma stockholders equity
48,788
57,934
67,480
80,235
Noncontrolling interest in pangu biopharma limited
-194
-193
-192
-191
Total stockholders' equity
48,594
57,741
67,288
80,044
Total liabilities and stockholders equity
69,825
79,654
93,003
106,652
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Available-for-sale investments$41,258K (-34.64%↓ Y/Y)Cash and cashequivalents$16,160K (-6.16%↓ Y/Y)Prepaid expenses$518K (-92.21%↓ Y/Y)Other receivables$426K (-14.46%↓ Y/Y)Total current assets$58,362K (-33.29%↓ Y/Y)Operating lease,right-of-use assets$5,353K (-5.72%↓ Y/Y)Property and equipment,net$4,127K (-8.82%↓ Y/Y)Restricted cash$1,495K (-48.05%↓ Y/Y)Financing lease,right-of-use assets$298K (-66.67%↓ Y/Y)Other assets$190K (187.88%↑ Y/Y)Total assets$69,825K (-31.23%↓ Y/Y)Total liabilities andstockholders equity$69,825K (-31.23%↓ Y/Y)Total stockholders'equity$48,594K (-34.91%↓ Y/Y)Total currentliabilities$11,396K (-26.62%↓ Y/Y)Long-term operating leaseliability, net of current...$9,799K (-8.80%↓ Y/Y)Long-term financing leaseliability, net of current...$36K (-94.02%↓ Y/Y)Noncontrolling interest inpangu biopharma...-$194K (-2.65%↓ Y/Y)Total atyr pharmastockholders equity$48,788K (-34.81%↓ Y/Y)Accrued expenses$6,690K (-35.17%↓ Y/Y)Accounts payable$3,242K (-16.46%↓ Y/Y)Current portion ofoperating lease liability$946K (23.02%↑ Y/Y)Current portion offinancing lease liability$518K (-7.83%↓ Y/Y)Accumulated deficit-$627,264K (-10.73%↓ Y/Y)Accumulated othercomprehensive loss-$68K (9.33%↑ Y/Y)Additional paid-in capital$676,022K (5.42%↑ Y/Y)Common stock, 0.001 parvalue per share...$98K (5.38%↑ Y/Y)

aTYR PHARMA INC (ATYR)

aTYR PHARMA INC (ATYR)